The Abortion Pill Lie: 40,960 Emergency Room Visits in Five Years
Townhall
By Jordan Sekulow
When mifepristone, sometimes known as the abortion pill, was approved by the FDA in 2000, it was placed under a strict Risk Evaluation and Mitigation Strategy (REMS) due to serious safety concerns. That original REMS framework remained largely intact for over two decades – until, as you might expect, the Biden administration intervened. For years, mifepristone had to be dispensed in person by certified providers. But in December 2021, despite the proven risks, the FDA permanently removed that safeguard, allowing the abortion pill to be prescribed via telehealth and shipped directly through the mail.
However, in a major step forward for the pro-life movement and for the protection of women’s health, President Trump’s FDA Commissioner, Dr. Marty Makary, pledged that the FDA would “conduct a review” of its approval of mifepristone. This is a critical victory – not just for unborn children but for the women whose health has been tossed aside by a radical abortion agenda. This comes just two weeks after we sent a letter to FDA Commissioner Makary asking for the agency’s intervention on behalf of women and babies.
The ACLJ has long warned about this very danger. In our letter, we detailed how the Biden administration recklessly expanded access to mifepristone through mail-order abortion and by stripping away critical safety protocols. We are urging federal officials to roll back this politically motivated deregulation and restore medically necessary safeguards. Come alongside us in our efforts and sign our petition: Defeat the Abortion Pill.